S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:BCRX

BioCryst Pharmaceuticals News Headlines

$11.15
+0.23 (+2.11 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.69
Now: $11.15
$11.19
50-Day Range
$8.52
MA: $9.98
$11.98
52-Week Range
$1.58
Now: $11.15
$12.90
Volume8.55 million shs
Average Volume7.20 million shs
Market Capitalization$1.98 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.03

Headlines

BioCryst Pharmaceuticals (NASDAQ BCRX) News Headlines Today

Source:
SourceHeadline
TheStreet Downgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) to D-TheStreet Downgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) to D-
marketbeat.com - February 27 at 7:04 AM
BioCryst Pharmaceuticals (NASDAQ:BCRX)  Shares Down 8% BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 8%
americanbankingnews.com - March 4 at 9:02 PM
BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary AngioedemaBioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
finance.yahoo.com - March 2 at 9:24 AM
Why BioCryst Pharmaceuticals Stock Is Popping TodayWhy BioCryst Pharmaceuticals Stock Is Popping Today
finance.yahoo.com - March 1 at 6:01 PM
Cowen Begins Coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX)Cowen Begins Coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX)
americanbankingnews.com - March 1 at 8:33 AM
Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) & Dyadic International (NASDAQ:DYAI)Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) & Dyadic International (NASDAQ:DYAI)
americanbankingnews.com - February 27 at 4:48 PM
BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly  Earnings Results, Misses Expectations By $0.09 EPSBioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results, Misses Expectations By $0.09 EPS
americanbankingnews.com - February 26 at 6:10 PM
BioCrysts Orladeyo Wins EU Positive Opinion For Hereditary AngioedemaBioCryst's Orladeyo Wins EU Positive Opinion For Hereditary Angioedema
finance.yahoo.com - February 26 at 12:29 PM
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 11.3%BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 11.3%
americanbankingnews.com - February 25 at 10:00 PM
BioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary AngioedemaBioCryst Receives Positive CHMP Opinion for ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema
finance.yahoo.com - February 25 at 8:32 PM
BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call TranscriptBioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript
msn.com - February 25 at 3:31 PM
Why BioCryst Pharmaceuticals Stock Is Falling TodayWhy BioCryst Pharmaceuticals Stock Is Falling Today
fool.com - February 25 at 2:22 PM
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue EstimatesBioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates
msn.com - February 25 at 10:11 AM
BioCryst Pharmaceuticals, Inc. to Host Earnings CallBioCryst Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - February 25 at 10:11 AM
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key MilestonesBioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
finance.yahoo.com - February 25 at 10:11 AM
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 6.5% Higher BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 6.5% Higher
americanbankingnews.com - February 24 at 9:16 PM
BioCryst Pharmaceuticals (BCRX) Set to Announce Earnings on ThursdayBioCryst Pharmaceuticals (BCRX) Set to Announce Earnings on Thursday
americanbankingnews.com - February 18 at 2:48 AM
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 8%BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 8%
americanbankingnews.com - February 16 at 8:22 PM
What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.s (NASDAQ:BCRX) Shares?What Kind Of Shareholders Hold The Majority In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares?
finance.yahoo.com - February 7 at 8:48 AM
BioCryst climbs after FDA approval for Rapivab in infantsBioCryst climbs after FDA approval for Rapivab in infants
seekingalpha.com - February 5 at 12:14 AM
BioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and OlderBioCryst Announces FDA Approval of Supplemental New Drug Application for RAPIVAB® Expanding Patient Population to Include Children Six Months and Older
finance.yahoo.com - February 3 at 8:00 AM
BioCryst Pharmaceuticals Reaches Analyst Target PriceBioCryst Pharmaceuticals Reaches Analyst Target Price
nasdaq.com - February 2 at 2:45 PM
The GameStop frenzy convinced more people to search how to buy stocks than last years surgeThe GameStop frenzy convinced more people to search 'how to buy stocks' than last year's surge
finance.yahoo.com - February 2 at 2:45 PM
Reddit Traders Declare ‘BioWar’ as Shorted Biotechs SoarReddit Traders Declare ‘BioWar’ as Shorted Biotechs Soar
finance.yahoo.com - February 1 at 6:35 PM
Options Surge Could Work in BioCrysts Favor TodayOptions Surge Could Work in BioCryst's Favor Today
marketwatch.com - February 1 at 1:34 PM
BioCryst (BCRX) Wins Japanese Approval for HAE Drug OrladeyoBioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo
finance.yahoo.com - January 25 at 1:47 PM
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary AngioedemaBioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
finance.yahoo.com - January 22 at 8:52 AM
First Week of September 17th Options Trading For BioCryst Pharmaceuticals (BCRX)First Week of September 17th Options Trading For BioCryst Pharmaceuticals (BCRX)
nasdaq.com - January 15 at 6:37 PM
BioCryst to Present at 39th Annual J.P. Morgan Healthcare ConferenceBioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 9:01 AM
2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started
finance.yahoo.com - December 23 at 9:31 AM
Why BioCryst Pharmaceuticals Stock Is Sinking TodayWhy BioCryst Pharmaceuticals Stock Is Sinking Today
finance.yahoo.com - December 22 at 1:11 PM
BioCryst Provides Update on Galidesivir ProgramBioCryst Provides Update on Galidesivir Program
finance.yahoo.com - December 22 at 8:10 AM
BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans ProgressivaBioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva
finance.yahoo.com - December 21 at 9:30 AM
Is BCRX A Good Stock To Buy Now According To Hedge Funds?Is BCRX A Good Stock To Buy Now According To Hedge Funds?
finance.yahoo.com - December 18 at 11:39 PM
First Week of BCRX February 2021 Options TradingFirst Week of BCRX February 2021 Options Trading
nasdaq.com - December 18 at 1:33 PM
BioCryst Announces U.S. Availability of ORLADEYO(TM) (berotralstat) for the Treatment of Hereditary AngioedemaBioCryst Announces U.S. Availability of ORLADEYO(TM) (berotralstat) for the Treatment of Hereditary Angioedema
marketwatch.com - December 17 at 12:30 AM
BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary AngioedemaBioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema
finance.yahoo.com - December 16 at 9:29 AM
BioCryst to Present at JMP Securities Hematology SummitBioCryst to Present at JMP Securities Hematology Summit
finance.yahoo.com - December 11 at 7:24 AM
BioCryst Pharmaceuticals: Orladeyo Approved, Financing Overhang RemovedBioCryst Pharmaceuticals: Orladeyo Approved, Financing Overhang Removed
seekingalpha.com - December 10 at 6:27 AM
Durham drugmaker secures $325M to support commercial launchDurham drugmaker secures $325M to support commercial launch
bizjournals.com - December 9 at 11:04 PM
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Insiders Increased Their HoldingsBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Insiders Increased Their Holdings
finance.yahoo.com - December 9 at 8:08 AM
BioCryst: Time To Switch Hats? A Mid Cap Fits Now, Maybe A Large Cap?BioCryst: Time To Switch Hats? A Mid Cap Fits Now, Maybe A Large Cap?
seekingalpha.com - December 8 at 8:44 AM
BioCrysts Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of ComplementBioCryst's Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement
benzinga.com - December 6 at 5:07 PM
BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of ComplementBioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement
finance.yahoo.com - December 6 at 5:07 PM
Durham drugmaker reaches huge milestone, looks ahead to $500M goalDurham drugmaker reaches huge milestone, looks ahead to $500M goal
bizjournals.com - December 4 at 5:30 PM
Looking Into Biocryst Pharmaceuticalss Return On Capital EmployedLooking Into Biocryst Pharmaceuticals's Return On Capital Employed
benzinga.com - December 4 at 5:30 PM
Why BioCryst Stock Is Crushing It TodayWhy BioCryst Stock Is Crushing It Today
fool.com - December 4 at 5:30 PM
BioCryst (BCRX) Wins FDA Approval for HAE Drug OrladeyoBioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
nasdaq.com - December 4 at 5:30 PM
BioCryst Announces FDA Approval of ORLADEYO(TM) (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema PatientsBioCryst Announces FDA Approval of ORLADEYO(TM) (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
marketwatch.com - December 4 at 3:15 AM
FDA Approves BioCrysts Hereditary Angioedema Drug - Japan & Europe Next?FDA Approves BioCryst's Hereditary Angioedema Drug - Japan & Europe Next?
nasdaq.com - December 4 at 3:15 AM
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema PatientsBioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
finance.yahoo.com - December 3 at 10:15 PM
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.